Has Chenyu Lin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $40,061 in general payments to Chenyu Lin, MD across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chenyu Lin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chenyu Lin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chenyu Lin, MD

Hematology & Oncology · Durham, NCNPI 1093177545

Payments from drug & device makers

$40,061in general payments, 2019–2025

Across 22 payments — averaging $1820.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$27K
ADC Therapeutics America, Inc.$10K
Autolus Inc$2K
Daiichi Sankyo Inc.$650
AbbVie$207
Jazz Pharmaceuticals Inc.$147
plus $375 from 4 others

What the payments were for

Consulting fees$9,05067%
Speaking & faculty fees$2,34017%
Travel & lodging$8426%
Food & beverage$1,2009%
Education$831%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	2	$26,659
ADC Therapeutics America, Inc.	10	$9,551
Autolus Inc	2	$2,471
Daiichi Sankyo Inc.	1	$650
AbbVie	2	$207
Jazz Pharmaceuticals Inc.	1	$147
Johnson & Johnson	1	$125
Gilead	1	$125
Beigene USA, Inc.	1	$86
Rigel Pharmaceuticals, Inc.	1	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,061 in reported general payments places this provider in the 65th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$36,720

Medicare patients

Services billed

433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Acyclovir	59	$688
Prochlorperazine Maleate	12	$130
Prednisone	32	$88
Ondansetron Hcl	11	$69

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Durham

Kimberly BlackwellDurham$13.2M
Danielle BranderDurham$8.6M
Michael MorseDurham$6M
Jameel MuzaffarDurham$3.5M
Matthew McKinneyDurham$2.9M
Andrea SitlingerDurham$2M
Kimberly WymanDurham$1.5M
Syed ZafarDurham$978K
Soheir AdamDurham$855K
Yubin KangDurham$850K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →